Skip to main content
Home > Week in Review > Deals

Chronological Index of : Deals

 Current Issue
  • AbVitro, Roche deal

    AbVitro Inc., Boston, Mass. Roche (SIX:ROG;OTCQX:RHHBY), Basel, Switzerland Business: Genomics, High throughput screening AbVitro granted Roche exclusive rights to primer extension-based target enrichment (PETE) …

    Published on 11/24/2014
  • Access Pharmaceuticals, Norgine Beta.V. deal

    Access Pharmaceuticals Inc., Dallas, Texas Norgine Beta.V., Amsterdam, the Netherlands Business: Other PlasmaTech (formerly Access Pharmaceuticals Inc.) and Norgine added Australia and New Zealand to an August deal …

    Published on 11/24/2014
  • Advinus, Takeda deal

    Advinus Therapeutics Ltd., Pune, India Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), Osaka, Japan Business: Neurology, Endocrine/Metabolic, Inflammation Advinus received a $3 million milestone payment from Takeda under a…

    Published on 11/24/2014
  • Alios, J&J deal

    Alios BioPharma Inc., South San Francisco, Calif. Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Business: Infectious Johnson & Johnson completed its acquisition of Alios for about $1.8 billion in cash (see …

    Published on 11/24/2014
  • Allergan, Actavis deal

    Allergan Inc. (NYSE:AGN), Irvine, Calif. Actavis plc (NYSE:ACT), Dublin, Ireland Business: Pharmaceuticals Actavis said it will acquire Allergan for $66 billion, or $219 per share. The price represents a 10% premium to …

    Published on 11/24/2014
  • Almirall, AstraZeneca deal

    Almirall S.A. (Madrid:ALM), Barcelona, Spain AstraZeneca plc (LSE:AZN;NYSE:AZN), London, U.K. Business: Pulmonary, Inflammation AstraZeneca completed its purchase of Almiralls respiratory disease business for $875 …

    Published on 11/24/2014
  • Ambit, Daiichi Sankyo deal

    Ambit Biosciences Corp., San Diego, Calif. Daiichi Sankyo Co. Ltd. (Tokyo:4568), Tokyo, Japan Business: Cancer Daiichi completed its acquisition of Ambit (see BioCentury, Oct. 27).

    Published on 11/24/2014
  • Biofrontera, Allergan deal

    Biofrontera AG (Xetra:B8F), Leverkusen, Germany Allergan Inc. (NYSE:AGN), Irvine, Calif. Business: Dermatology, Cancer Allergan will return to Biofrontera Spanish distribution rights to Ameluz and BF-RhodoLED, effective…

    Published on 11/24/2014
  • Bionomics, Ironwood deal

    Bionomics Ltd. (ASX:BNO;OTCBB:BMICY), Thebarton, Australia Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD), Cambridge, Mass. Business: Neurology Bionomics and Ironwood mutually terminated a 2012 deal granting Ironwood …

    Published on 11/24/2014
  • Broad Institute, Takara Bio deal

    Broad Institute of MIT and Harvard, Cambridge, Mass. Takara Bio Inc. (Tokyo:4974), Shiga, Japan Business: Genomics Takaras Clontech Laboratories Inc. subsidiary received non-exclusive rights to Broads IP related to …

    Published on 11/24/2014
  • Caribou Biosciences, Intellia Therapeutics deal

    Caribou Biosciences Inc., Berkeley, Calif. Intellia Therapeutics Inc., Cambridge, Mass. Business: Functional genomics Caribou granted newco Intellia an exclusive, worldwide sublicense to Caribous CRISPR/Cas9 genome …

    Published on 11/24/2014
  • CureTech, Medivation deal

    CureTech Ltd., Yavne, Israel Medivation Inc. (NASDAQ:MDVN), San Francisco, Calif. Business: Cancer Medivation received exclusive, worldwide rights to CureTechs pidilizumab (CT-011), a humanized anti-programmed cell …

    Published on 11/24/2014
  • Cystic Fibrosis Foundation, Royalty Pharma deal

    Cystic Fibrosis Foundation, Bethesda, Md. Royalty Pharma, New York, N.ZZZ. Business: Pulmonary Royalty Pharma purchased from the foundation for $3.3 billion in cash the royalty rights for cystic fibrosis treatments …

    Published on 11/24/2014
  • CytoSorbents, Biocon deal

    CytoSorbents Corp. (OTCBB:CTSO), Monmouth Junction, N.J. Biocon Ltd. (NSE:BIOCON;BSE:BIOCON), Bangalore, India Business: Infectious Biocon and CytoSorbents expanded their 2013 deal and Biocon will now have exclusive, …

    Published on 11/24/2014
  • CyVek, Bio-Techne deal

    CyVek Inc., Wallingford, Conn. Bio-Techne (NASDAQ:TECH), Minneapolis, Minn. Business: Diagnostic Bio-Techne acquired diagnostic company CyVek for $62 million in cash plus a potential earn-out payment tied to sales of up…

    Published on 11/24/2014
  • Durata Therapeutics, Actavis deal

    Durata Therapeutics Inc. (NASDAQ:DRTX), Chicago, Ill. Actavis plc (NYSE:ACT), Dublin, Ireland Business: Infectious Actavis completed its acquisition of Durata for $23 per share in cash up front, or $675 million, plus up…

    Published on 11/24/2014
  • Eisai, Hikma Pharmaceuticals deal

    Eisai Co. Ltd. (Tokyo:4523), Tokyo, Japan Hikma Pharmaceuticals plc (LSE:HIK), London, U.K. Business: Neurology Hikma received rights to distribute Eisais epilepsy drug Fycompa perampanel in the Middle East. The five-…

    Published on 11/24/2014
  • General Electric, Takeda deal

    General Electric Co. (NYSE:GE), Fairfield, Conn. Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), Osaka, Japan Business: Hepatic GEs GE Healthcare unit and Takeda partnered to research hepatic fibrosis to diagnose and treat…

    Published on 11/24/2014
  • Ikaria, Lees Pharmaceutical Holdings Ltd. deal

    Ikaria Inc., Hampton, N.J. Lees Pharmaceutical Holdings Ltd. (HKSE:0950), Hong Kong, China Business: Pulmonary Ikaria granted Lees rights to INOmax nitric oxide in China, including Hong Kong and Macau, and Taiwan. The …

    Published on 11/24/2014
  • Intra-Cellular, Takeda deal

    Intra-Cellular Therapies Inc. (NASDAQ:ITCI), New York, N.ZZZ. Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), Osaka, Japan Business: Neurology Intra-Cellular and Takeda mutually terminated a 2011 deal granting the pharma …

    Published on 11/24/2014
  • Isis Pharmaceuticals, AstraZeneca deal

    Isis Pharmaceuticals Inc. (NASDAQ:ISIS), Carlsbad, Calif. AstraZeneca plc (LSE:AZN;NYSE:AZN), London, U.K. Business: Cancer Isis received a $7.5 million milestone payment from AstraZeneca under a December 2012 deal to …

    Published on 11/24/2014
  • Isis Pharmaceuticals, GlaxoSmithKline deal

    Isis Pharmaceuticals Inc. (NASDAQ:ISIS), Carlsbad, Calif. GlaxoSmithKline plc (LSE:GSK;NYSE:GSK), London, U.K. Business: Ophthalmic Isis received a $5 million payment from GlaxoSmithKline under an amended 2010 deal to …

    Published on 11/24/2014
  • Japan Tobacco, Leo Pharma deal

    Japan Tobacco Inc. (Tokyo:2914), Tokyo, Japan Leo Pharma A/S, Ballerup, Denmark Business: Dermatology Japan Tobacco granted Leo exclusive, ex-Japan rights to develop and commercialize JTE-052 for topical use to treat …

    Published on 11/24/2014
  • Lanthio Pharma Beta.V., MorphoSys deal

    Lanthio Pharma Beta.V., Groningen, the Netherlands MorphoSys AG (Xetra:MOR;Pink:MPSYF), Martinsried, Germany Business: Antibodies MorphoSys exercised its option under a 2012 deal to purchase Lanthios lanthipeptide …

    Published on 11/24/2014
  • Lexicon, Ipsen deal

    Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX), The Woodlands, Texas Ipsen Group (Euronext:IPN;Pink:IPSEY), Boulogne-Billancourt, France Business: Cancer Ipsen received an exclusive license from Lexicon to commercialize …

    Published on 11/24/2014

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993